52 related articles for article (PubMed ID: 26130140)
21. Epidermal growth factor receptor mutation heterogeneity analysis of pulmonary sarcomatoid carcinoma successfully treated with erlotinib: A case report.
Zou F; Xie G; Ma JA; Zhou DA; Jiang YI; Zheng JY
Oncol Lett; 2015 May; 9(5):2239-2243. PubMed ID: 26137049
[TBL] [Abstract][Full Text] [Related]
22. Association between EML4-ALK fusion gene and thymidylate synthase mRNA expression in non-small cell lung cancer tissues.
Xu CW; Wang G; Wang WL; Gao WB; Han CJ; Gao JS; Zhang LY; Li Y; Wang L; Zhang YP; Tian YW; Qi DD
Exp Ther Med; 2015 Jun; 9(6):2151-2154. PubMed ID: 26136951
[TBL] [Abstract][Full Text] [Related]
23. Identification of a Novel ALK G1123S Mutation in a Patient with ALK-rearranged Non-small-cell Lung Cancer Exhibiting Resistance to Ceritinib.
Toyokawa G; Inamasu E; Shimamatsu S; Yoshida T; Nosaki K; Hirai F; Yamaguchi M; Seto T; Takenoyama M; Ichinose Y
J Thorac Oncol; 2015 Jul; 10(7):e55-7. PubMed ID: 26134233
[No Abstract] [Full Text] [Related]
24. Five water-soluble zwitterionic copper(II)-carboxylate polymers: role of dipyridyl coligands in enhancing the DNA-binding, cleaving and anticancer activities.
Chen M; Tang XY; Yang SP; Li HH; Zhao HQ; Jiang ZH; Chen JX; Chen WH
Dalton Trans; 2015 Aug; 44(29):13369-77. PubMed ID: 26131732
[TBL] [Abstract][Full Text] [Related]
25. A systematic analysis of human lipocalin family and its expression in esophageal carcinoma.
Du ZP; Wu BL; Wu X; Lin XH; Qiu XY; Zhan XF; Wang SH; Shen JH; Zheng CP; Wu ZY; Xu LY; Wang D; Li EM
Sci Rep; 2015 Jul; 5():12010. PubMed ID: 26131602
[TBL] [Abstract][Full Text] [Related]
26. Exploring potential genes and pathways related to lung cancer: a graph theoretical analysis.
Hayat S; Ishrat R
Bioinformation; 2023; 19(9):954-963. PubMed ID: 37928493
[TBL] [Abstract][Full Text] [Related]
27. Case report: Concomitant
Hu H; Tan S; Xie M; Guo P; Yu Q; Xiao J; Zhao K; Liao Q; Wang Y
Front Pharmacol; 2023; 14():1167959. PubMed ID: 37705536
[TBL] [Abstract][Full Text] [Related]
28. Lung adenocarcinoma with EGFR 19Del and an ALK rearrangement benefits from alectinib instead of an EGFR-TKI: A case report.
Wang H; Zhu S; Li Z; Qi X; Zhang L; Ke L; Lin Y
Medicine (Baltimore); 2022 Sep; 101(35):e30316. PubMed ID: 36107507
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness of alectinib and osimertinib in a brain metastasized lung adenocarcinoma patient with concurrent EGFR mutations and DCTN1-ALK fusion.
Yin Q; Guo T; Zhou Y; Sun L; Meng M; Ma L; Wang X
Thorac Cancer; 2022 Feb; 13(4):637-642. PubMed ID: 34964276
[TBL] [Abstract][Full Text] [Related]
30. Clinicopathological features and diagnostic methods of ALK fusion‑positive non‑small cell lung cancer in Korea.
Chang WC; Kim HK; Shin BK
Oncol Rep; 2020 Jan; 43(1):218-228. PubMed ID: 31746406
[TBL] [Abstract][Full Text] [Related]
31. Challenges of Providing Concordant Interpretation of Somatic Variants in Non-Small Cell Lung Cancer: A Multicenter Study.
Gao P; Zhang R; Li Z; Ding J; Xie J; Li J
J Cancer; 2019; 10(8):1814-1824. PubMed ID: 31205538
[No Abstract] [Full Text] [Related]
32. Integrated analysis reveals key genes with prognostic value in lung adenocarcinoma.
Song YJ; Tan J; Gao XH; Wang LX
Cancer Manag Res; 2018; 10():6097-6108. PubMed ID: 30538558
[TBL] [Abstract][Full Text] [Related]
33. Simultaneous VENTANA IHC and RT-PCR testing of ALK status in Chinese non-small cell lung cancer patients and response to crizotinib.
Xu CW; Wang WX; Chen YP; Chen Y; Liu W; Zhong LH; Chen FF; Zhuang W; Song ZB; Chen XH; Huang YJ; Guan YF; Yi X; Lv TF; Zhu WF; Lu JP; Wang XJ; Shi Y; Lin XD; Chen G; Song Y
J Transl Med; 2018 Apr; 16(1):93. PubMed ID: 29642919
[TBL] [Abstract][Full Text] [Related]
34. Concomitant
Lo Russo G; Imbimbo M; Corrao G; Proto C; Signorelli D; Vitali M; Ganzinelli M; Botta L; Zilembo N; de Braud F; Garassino MC
Oncotarget; 2017 Aug; 8(35):59889-59900. PubMed ID: 28938691
[TBL] [Abstract][Full Text] [Related]
35. Responses to crizotinib and chemotherapy in patients with lung adenocarcinoma harboring a concomitant
Li Y; Su S; Cai G; Lin Q; Zhou Y; Ouyang J; Chen B; Ye J; Wu X; Chen C
Mol Clin Oncol; 2017 Aug; 7(2):173-182. PubMed ID: 28781781
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic MicroRNA Biomarker Discovery for Non-Small-Cell Lung Cancer Adenocarcinoma by Integrative Bioinformatics Analysis.
Shao Y; Liang B; Long F; Jiang SJ
Biomed Res Int; 2017; 2017():2563085. PubMed ID: 28698868
[TBL] [Abstract][Full Text] [Related]
37. Metastatic EML4-ALK fusion detected by circulating DNA genotyping in an EGFR-mutated NSCLC patient and successful management by adding ALK inhibitors: a case report.
Liang W; He Q; Chen Y; Chuai S; Yin W; Wang W; Peng G; Zhou C; He J
BMC Cancer; 2016 Feb; 16():62. PubMed ID: 26850068
[TBL] [Abstract][Full Text] [Related]
38. A case of lung adenocarcinoma with a concurrent EGFR mutation and ALK rearrangement: A case report and literature review.
Xu CW; Cai XY; Shao Y; Li Y; Shi MW; Zhang LY; Wang L; Zhang YP; Wang LP; Tian YW
Mol Med Rep; 2015 Sep; 12(3):4370-4375. PubMed ID: 26130140
[TBL] [Abstract][Full Text] [Related]
39. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.
Cai G; Wong R; Chhieng D; Levy GH; Gettinger SN; Herbst RS; Puchalski JT; Homer RJ; Hui P
Cancer Cytopathol; 2013 Sep; 121(9):500-7. PubMed ID: 23495083
[TBL] [Abstract][Full Text] [Related]
40. EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR.
Wu SG; Kuo YW; Chang YL; Shih JY; Chen YH; Tsai MF; Yu CJ; Yang CH; Yang PC
J Thorac Oncol; 2012 Jan; 7(1):98-104. PubMed ID: 22124476
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
